drugset / Trial / NCT04200781

Clinical Evaluation of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke

NCT04200781 ↗

Phase 4 Unknown 464 enrolled ShuGuang Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Shengdi Dahuang Decoction in the treatment of acute hemorrhagic stroke by the randomized, controlled, double-blind, multi-center trial design project.

Timeline

Start
2019-09-01
Primary completion
2022-06-30
Completion
2022-06-30

Outcome

Met primary endpoint

paper 112 (46.3%) and 84 (34.9%) patients in the SDD and placebo groups, respectively, had an mRS score of 0-1 PMID 40752894 ↗

paper had an mRS score of 0-1 on the 90th day (adjusted relative risk 1.20, 95% CI 1.00 to 1.43; p=0.046) PMID 40752894 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Shengdi Dahuang Decoction Traditional medicine (herbal / TCM) — Oral

Indications